The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II study of binimetinib plus imatinib in patients with unresectable KIT-mutant melanoma.
 
Katy Tsai
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene
Research Funding - ABM (Inst); AstraZeneca (Inst); BioAtla (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Georgiamune (Inst); IDEAYA Biosciences (Inst); Innovent Biologics (Inst); Merck (Inst); Oncosec (Inst); OnKure (Inst); Pfizer (Inst); Replimune (Inst)
 
Gregory Daniels
Research Funding - BioAtla (Inst); Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); IDEAYA Biosciences (Inst); Imugene (Inst); Merck (Inst); Pfizer (Inst); Regeneron (Inst); Regeneron (Inst); Replimune (Inst)
 
Marjan Rajabi
No Relationships to Disclose
 
Nicholas Lee
No Relationships to Disclose
 
Adil Daud
Stock and Other Ownership Interests - Neuvogen; Trex bio
Honoraria - EMD Serono; Inovio Pharmaceuticals
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Genoptix; GlaxoSmithKline; Merck; Oncosec; Pfizer
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Checkmate Pharmaceuticals; Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte; Merck/Schering Plough (Inst); Novartis; oncosec (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - patent relating to test for immunotherapy
 
Iwei Yeh
Research Funding - Pfizer (Inst)